Neurologic Deterioration Following Immune Checkpoint Inhibitor Therapy in a Patient With HAM / TSP
Authors:
- 22 April 2026
- journal article
- Published by Wiley in Neurology and Clinical Neuroscience
Abstract
Introduction: HTLV‐1 is a human retrovirus that targets T lymphocytes and can cause human T‐cell lymphotropic virus type‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP). HAM/TSP is a rare, chronic, neuroinflammatory disorder characterized by progressive lower‐extremity stiffness and weakness. Case Presentation: We present a 50‐year‐old man with a history of HAM/TSP who developed Lynch syndrome with synchronous gastrointestinal cancers and experienced acute neurological worsening following pembrolizumab therapy. Conclusion: This case highlights the potential for immune checkpoint inhibitor–related neuroinflammatory exacerbation in a patient with HTLV‐1 infection.Keywords
This publication has 16 references indexed in Scilit:
- Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting systemInternational Journal of Cancer, 2024
- HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): Case based discussion of risk factors, clinical, and therapeutic considerationsJournal of the Neurological Sciences, 2024
- Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathyExpert Review of Neurotherapeutics, 2023
- An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkersPharmacology & Therapeutics, 2021
- Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion UpdateJournal of Clinical Oncology, 2020
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Identification of Lynch Syndrome Among Patients With Colorectal CancerJAMA, 2012
- Programmed death-1 (PD-1)/PD-1 ligand pathway–mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disordersHuman Immunology, 2011
- Clinical Relevance of Microsatellite Instability in Colorectal CancerJournal of Clinical Oncology, 2010
- Human T Lymphotropic Virus Type 1 Infection and Gastric Cancer Development in JapanThe Journal of Infectious Diseases, 2008